John Lambourne

John Lambourne has a wealth of work experience in the life sciences industry. From 2002 to 2008, they worked as a Fermentor Technician at Lonza, a Global Leader in Life Sciences. From 2008 to 2011, they were a Senior R&D Scientist at Scipac Ltd, where they were responsible for introducing recombinant protein expression platforms. From 2011 to 2014, they were a Postdoctoral Fellow at McGill University, where they led the chromatin modelling pipeline for the Epigenome Mapping Centre (EMC). From 2014 to 2018, they were a Research Associate at the University of Cambridge, where they applied functional genomics approaches for drug discovery. From 2018 to 2022, they were a Research and Development Manager and Senior Scientist I at Horizon Discovery, where they led a high-performance team of senior scientists in world class data generation relevant for the Cell and Gene therapy space. Currently, they are the Head of Molecular Biology - Principal Scientist at Transine Therapeutics, where they lead a molecular biology team to enable both pipeline and platform research capabilities in the therapeutic development of SINEUP (ncRNA) technology.

John Lambourne has an extensive educational background. John obtained their Doctor of Philosophy (PhD) in Protein Science from the University of Reading in 2008 after completing a Bachelor of Science (BSc) in Biotechnology at the same institution in 2004. Prior to that, they obtained A-Levels in Mathematics, Physics, and Biology from Hillcrest in 2001. In addition to their formal education, John has obtained two certifications. John is a Biological Safety Officer Qualified from IOSH East Anglia Branch, which they obtained in July 2022, and an APM Project Management Qualification (PMQ) from the Association for Project Management, which they obtained in December 2021.